VAT Group AG (LON:0RFL)
London · Delayed Price · Currency is GBP · Price in CHF 289.91
-3.68 (-1.25%)
At close: Jul 31, 2025
CTI BioPharma Income Statement
Financials in millions CHF. Fiscal year is January - December.
Millions CHF. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 1,051 | 942.2 | 885.32 | 1,145 | 901.16 | 692.43 | Upgrade | |
Revenue Growth (YoY) | 19.22% | 6.42% | -22.71% | 27.11% | 30.14% | 21.40% | Upgrade |
Cost of Revenue | 381.45 | 339.93 | 357.91 | 437.31 | 351.19 | 277.87 | Upgrade |
Gross Profit | 669.11 | 602.27 | 527.41 | 708.17 | 549.97 | 414.56 | Upgrade |
Selling, General & Admin | 264.66 | 247.3 | 214.96 | 231.86 | 202.46 | 176.92 | Upgrade |
Other Operating Expenses | 86.16 | 67.35 | 66.18 | 75.5 | 51.06 | 41.17 | Upgrade |
Operating Expenses | 395.75 | 358.1 | 322.55 | 347.58 | 293.58 | 258.5 | Upgrade |
Operating Income | 273.36 | 244.17 | 204.86 | 360.6 | 256.38 | 156.07 | Upgrade |
Interest Expense | -17.69 | -5.77 | -5.31 | -3.58 | -3.52 | -4.08 | Upgrade |
Interest & Investment Income | - | 1.28 | 1.31 | 0.44 | 0.15 | 0.12 | Upgrade |
Currency Exchange Gain (Loss) | 2.32 | 2.32 | -5.66 | -9.73 | -1.1 | -7.57 | Upgrade |
Other Non Operating Income (Expenses) | 9.62 | 10.59 | 12.69 | 9.45 | 8.71 | 9.99 | Upgrade |
EBT Excluding Unusual Items | 267.61 | 252.59 | 207.88 | 357.18 | 260.62 | 154.53 | Upgrade |
Gain (Loss) on Sale of Assets | 0.04 | 0.04 | 0.12 | 0.02 | 0.11 | -0.01 | Upgrade |
Asset Writedown | -0.04 | -0.04 | -0.92 | -0.75 | -3 | -0.29 | Upgrade |
Pretax Income | 267.61 | 252.59 | 207.09 | 356.45 | 257.74 | 154.23 | Upgrade |
Income Tax Expense | 44.24 | 40.79 | 16.78 | 49.67 | 40.3 | 26.28 | Upgrade |
Net Income | 223.37 | 211.8 | 190.31 | 306.78 | 217.44 | 127.94 | Upgrade |
Net Income to Common | 223.37 | 211.8 | 190.31 | 306.78 | 217.44 | 127.94 | Upgrade |
Net Income Growth | 11.63% | 11.29% | -37.96% | 41.09% | 69.95% | 70.99% | Upgrade |
Shares Outstanding (Basic) | 30 | 30 | 30 | 30 | 30 | 30 | Upgrade |
Shares Outstanding (Diluted) | 30 | 30 | 30 | 30 | 30 | 30 | Upgrade |
Shares Change (YoY) | -0.10% | -0.02% | -0.02% | -0.04% | 0.05% | 0.02% | Upgrade |
EPS (Basic) | 7.44 | 7.06 | 6.35 | 10.23 | 7.25 | 4.27 | Upgrade |
EPS (Diluted) | 7.44 | 7.06 | 6.34 | 10.22 | 7.24 | 4.26 | Upgrade |
EPS Growth | 11.77% | 11.36% | -37.96% | 41.16% | 69.95% | 71.08% | Upgrade |
Free Cash Flow | 218.96 | 194 | 196.14 | 234.99 | 207.37 | 158.34 | Upgrade |
Free Cash Flow Per Share | 7.30 | 6.47 | 6.54 | 7.83 | 6.91 | 5.28 | Upgrade |
Dividend Per Share | 6.250 | 6.250 | 6.250 | 6.250 | 5.500 | 4.500 | Upgrade |
Dividend Growth | - | - | - | 13.64% | 22.22% | 12.50% | Upgrade |
Gross Margin | 63.69% | 63.92% | 59.57% | 61.82% | 61.03% | 59.87% | Upgrade |
Operating Margin | 26.02% | 25.91% | 23.14% | 31.48% | 28.45% | 22.54% | Upgrade |
Profit Margin | 21.26% | 22.48% | 21.50% | 26.78% | 24.13% | 18.48% | Upgrade |
Free Cash Flow Margin | 20.84% | 20.59% | 22.16% | 20.52% | 23.01% | 22.87% | Upgrade |
EBITDA | 314.03 | 283.36 | 241.67 | 396.18 | 292.29 | 192.33 | Upgrade |
EBITDA Margin | 29.89% | 30.08% | 27.30% | 34.59% | 32.44% | 27.78% | Upgrade |
D&A For EBITDA | 40.68 | 39.19 | 36.81 | 35.59 | 35.91 | 36.26 | Upgrade |
EBIT | 273.36 | 244.17 | 204.86 | 360.6 | 256.38 | 156.07 | Upgrade |
EBIT Margin | 26.02% | 25.91% | 23.14% | 31.48% | 28.45% | 22.54% | Upgrade |
Effective Tax Rate | 16.53% | 16.15% | 8.10% | 13.94% | 15.63% | 17.04% | Upgrade |
Updated Mar 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.